Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...

Candel Therapeutics, Inc. (NASDAQ:CADL) on Wednesday revealed final survival data from a phase 2a trial of CAN-2409 in ...

Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 ...

A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the U.S.

Durable complete response (CR) in a MCC patient treated with 15 mg/kg solnerstotug + cemiplimab. Patient continues on ...

ICI-based combinations are the preferred first-line therapy due to their proven superiority over TKI monotherapy, many patients were not receiving them,” the researchers wrote.

Chinese pharmaceutical companies are making significant inroads into the global oncology market, particularly with the development and approval of immune checkpoint inhibitors. These treatments, which ...

Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...

Lung cancer remains one of the most widespread and deadliest malignant tumors globally, with a particularly high mortality rate among all cancers. Recently, immunotherapy, particularly immune ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

Discover Lantern Pharma's transformative 2024 journey in precision oncology with AI breakthroughs, global trial expansions, and key clinical milestones ...